Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 2026-2029, 2007; 10.1373/clinchem.2007.091942
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rambaldi, D. C.
Right arrow Articles by Johann, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rambaldi, D. C.
Right arrow Articles by Johann, C.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2007;53:2026-2029.)
© 2007 American Association for Clinical Chemistry, Inc.

Abstracts of Oak Ridge Posters

An Analytical Method for Size and Shape Characterization of Blood Lipoproteins

Diana Cristina Rambaldi1, Andrea Zattoni1, Sonia Casolari1, Pierluigi Reschiglian1,a, Dierk Roessner2 and Christoph Johann2

(1 Department of Chemistry "G. Ciamician", Bologna, Italy; 2 Wyatt Technology Europe GmbH, Dernbach, Germany;

aaddress correspondence to this author at: Department of Chemistry "G. Ciamician", Via Selmi 2, 40126 Bologna, Italy; fax 39-0-51-2099452, e-mail pierluig.reschiglian@unibo.it)

The first 300 words of the full text of this article appear below.

Determination of total cholesterol (TC), HDL and LDL cholesterol, and triglycerides (TG) is used to assess lipoprotein abnormalities and coronary artery disease (CAD) risk. Furthermore, studies have demonstrated that small, dense LDL particles penetrate more easily into the arterial intima (1), exhibit increasing binding to arterial wall proteoglycans(2), and are more prone to oxidative stress(3). Small, dense LDL particles also have a prolonged plasma half-life because of their lower binding affinity for the LDL receptor(4). The presence of small, dense LDL particles in plasma is, therefore, considered to be proatherogenic.

Analytical methods for LDL size characterization are therefore expected to improve classification, diagnosis, and therapy of dyslipidemic patients. However, simple methods for routine LDL size measurement are not yet available. LDL size is mainly measured by nondenaturing PAGE (5), which is time-consuming and may be unsuitable for large numbers of samples. Easier methods for measuring LDL size have been proposed, including high-performance gel-filtration chromatography (HPGC)(6). Both PAGE and HPGC can give accurate size estimations only if appropriate standards are available. Moreover, recent studies have shown that LDL particles may be discoidal, with diameter and height that are not significantly correlated(7). PAGE and HPGC cannot give information on particle conformation.

Flow field-flow fractionation (FlFFF) is a separation technique in which macromolecules and particles are separated by the combined actions of an axial flow and a perpendicular cross-flow (8). No stationary phase is present, and the separation mechanism is sufficiently gentle not to alter the native structure of proteins and protein complexes(9). Proteins are fractionated according to their difference in diffusion, with retention time that is inversely proportional to the analyte diffusion coefficient. In principle, with the use of FlFFF it is possible to . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.